DK2931265T6 - Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi - Google Patents

Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi Download PDF

Info

Publication number
DK2931265T6
DK2931265T6 DK13862780.7T DK13862780T DK2931265T6 DK 2931265 T6 DK2931265 T6 DK 2931265T6 DK 13862780 T DK13862780 T DK 13862780T DK 2931265 T6 DK2931265 T6 DK 2931265T6
Authority
DK
Denmark
Prior art keywords
axl
inhibition
modified
peptides
signaling
Prior art date
Application number
DK13862780.7T
Other languages
English (en)
Other versions
DK2931265T3 (da
Inventor
Amato J Giaccia
Erinn Bruno Rankin
Jennifer R Cochran
Yu Miao
Susan Hershenson
Mihalis Kariolis
Douglas Jones
Katherine Fuh
Original Assignee
Univ Leland Stanford Junior
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2931265(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior, Aravive Biologics Inc filed Critical Univ Leland Stanford Junior
Publication of DK2931265T3 publication Critical patent/DK2931265T3/da
Application granted granted Critical
Publication of DK2931265T6 publication Critical patent/DK2931265T6/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK13862780.7T 2012-12-14 2013-12-12 Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi DK2931265T6 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14
PCT/US2013/074786 WO2014093690A1 (en) 2012-12-14 2013-12-12 Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy

Publications (2)

Publication Number Publication Date
DK2931265T3 DK2931265T3 (da) 2018-04-16
DK2931265T6 true DK2931265T6 (da) 2023-05-01

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17196662.5T DK3326622T3 (da) 2012-12-14 2013-12-12 Modificerede peptider og deres anvendelse ved hæmning af AXL-signalering inden for anti-metastaseterapi
DK13862780.7T DK2931265T6 (da) 2012-12-14 2013-12-12 Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17196662.5T DK3326622T3 (da) 2012-12-14 2013-12-12 Modificerede peptider og deres anvendelse ved hæmning af AXL-signalering inden for anti-metastaseterapi

Country Status (12)

Country Link
US (3) US9822347B2 (da)
EP (2) EP2931265B3 (da)
JP (2) JP6345690B2 (da)
AU (3) AU2013359179B2 (da)
CA (1) CA2894539C (da)
DK (2) DK3326622T3 (da)
ES (2) ES2862335T3 (da)
FI (1) FI2931265T6 (da)
HK (1) HK1256071A1 (da)
NO (1) NO3049208T3 (da)
PT (2) PT2931265T (da)
WO (1) WO2014093690A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
RU2556822C2 (ru) * 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
CA2894539C (en) 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
ES2834618T3 (es) 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6
JP7286179B2 (ja) * 2017-11-04 2023-06-05 アラヴァイヴ バイオロジクス，インコーポレイテッド Ａｘｌデコイ受容体を用いる転移性癌の治療方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030170794A1 (en) 1997-09-18 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en) 2002-09-24 2005-01-04 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
JP2006524496A (ja) 2003-04-18 2006-11-02 ノバルティス アクチエンゲゼルシャフト 骨関節炎の診断および処置のためのチロシンキナーゼを標的化する方法および組成物
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (en) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Mer diagnostic and therapeutic agents
WO2006118308A1 (ja) 2005-05-02 2006-11-09 Toray Industries, Inc. 食道ガン及び食道ガン転移診断のための組成物及び方法
EP2114983B8 (en) * 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
US20090087431A1 (en) 2007-07-02 2009-04-02 Wyeth Methods of treating bone disorders with modulators of axl
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
EA201100947A1 (ru) * 2008-12-19 2012-02-28 Новартис Аг Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
US8841424B2 (en) 2009-05-11 2014-09-23 U3 Pharma Gmbh Humanized AXL antibodies
RU2556822C2 (ru) * 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
AU2011326164B2 (en) 2010-11-08 2016-05-05 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
CA2894539C (en) 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
US20160266136A1 (en) * 2013-08-30 2016-09-15 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6

Also Published As

Publication number Publication date
AU2017272193A1 (en) 2017-12-21
AU2013359179B2 (en) 2017-10-05
EP3326622B1 (en) 2021-01-20
HK1256071A1 (zh) 2019-09-13
US11136563B2 (en) 2021-10-05
AU2019210662A1 (en) 2019-08-22
US9822347B2 (en) 2017-11-21
CA2894539A1 (en) 2014-06-19
WO2014093690A1 (en) 2014-06-19
JP2018154641A (ja) 2018-10-04
FI2931265T6 (fi) 2023-05-23
DK2931265T3 (da) 2018-04-16
NO3049208T3 (da) 2018-04-14
PT3326622T (pt) 2021-04-07
ES2862335T3 (es) 2021-10-07
EP2931265A1 (en) 2015-10-21
PT2931265T (pt) 2018-04-16
ES2665323T7 (es) 2023-06-15
EP3326622A1 (en) 2018-05-30
AU2013359179A1 (en) 2015-07-02
EP2931265B1 (en) 2018-01-31
ES2665323T3 (es) 2018-04-25
US20220220458A1 (en) 2022-07-14
EP2931265A4 (en) 2016-08-31
JP6345690B2 (ja) 2018-06-20
US20180030422A1 (en) 2018-02-01
JP6832887B2 (ja) 2021-02-24
JP2016510309A (ja) 2016-04-07
AU2019210662B2 (en) 2021-07-01
US20150315553A1 (en) 2015-11-05
EP2931265B3 (en) 2023-04-05
DK3326622T3 (da) 2021-04-06
CA2894539C (en) 2021-09-28

Similar Documents

Publication Publication Date Title
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
DK3241840T3 (da) Inhibering af AXL-signalering i anti-metastatisk terapi
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
DK3019483T3 (da) Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2931265T6 (da) Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi
DK3088353T3 (da) Bilirubinpartikler og deres fremstilling til anvendelse i terapi
DK3335709T3 (da) Gamma-hydroxybutyratsammensætninger og deres anvendelse til behandling af lidelser
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK2855736T3 (da) Elektrolysator og energisystem
DK3358011T3 (da) Peptid til inducering af regenerering af væv og anvendelse deraf
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3196022T3 (da) Trykningssystem og fremgangsmåde
DK3202760T3 (da) Pegylerede lipider og deres anvendelse til lægemiddelfremføring
DK3351239T3 (da) Prostamid-indeholdende intraokulære implantater og fremgangsmåder til anvendelse deraf
IL245213A0 (en) Inhibitors of human immunodeficiency virus replication
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK3024428T3 (da) Sammensætninger og fremgangsmåder til dental mineralisering
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2880155T3 (da) Anvendelse af den reduktive glycinvej til generering af formatotrofiske og autotrofiske mikroorganismer
DK2827883T3 (da) Tfpi-inhibitorer og fremgangsmåder til anvendelse
DK2688578T3 (da) MIA- (melanom-inhibitorisk aktivitet)-inhibitorer til forebyggelse og behandling af vitiligo